RESUMO
In the murine model, in utero hematopoietic cell transplantation (IUHCT) has been shown to achieve low levels of allogeneic chimerism and associated donor-specific tolerance permitting minimal conditioning postnatal hematopoietic stem cell transplantation (HSCT). In this pilot study, we investigated IUHCT in the canine leukocyte adhesion deficiency (CLAD) model. Haploidentical IUHCT resulted in stable low-level donor cell chimerism in all dogs that could be analyzed by sensitive detection methodology (4 of 10) through 18 months of follow-up. In the 2 CLAD recipients, low-level chimerism resulted in amelioration and complete reversal of the CLAD phenotype, respectively. Six recipients of IUHCT (5 carriers and 1 CLAD) subsequently received postnatal HSCT from the same haploidentical prenatal donor after minimal conditioning with busulfan 10 mg/kg. Chimerism in 2 of 5 CLAD carriers that underwent HSCT increased from < 1% pre-HSCT to sustained levels of 35% to 45%. Control animals undergoing postnatal haploidentical HSCT without IUHCT had no detectable donor chimerism. These results demonstrate that haploidentical IUHCT in the CLAD model can result in low-level donor chimerism that can prevent the lethal phenotype in CLAD dogs, and can result in donor-specific tolerance that can facilitate postnatal minimal conditioning HSCT.
Assuntos
Terapias Fetais/métodos , Transplante de Células-Tronco Hematopoéticas/métodos , Síndrome da Aderência Leucocítica Deficitária/terapia , Animais , Bussulfano/administração & dosagem , Inibidores da Dipeptidil Peptidase IV , Modelos Animais de Doenças , Cães , Feminino , Doença Enxerto-Hospedeiro/imunologia , Haploidia , Tolerância Imunológica , Imunossupressores/administração & dosagem , Síndrome da Aderência Leucocítica Deficitária/imunologia , Teste de Cultura Mista de Linfócitos , Masculino , Camundongos , Gravidez , Quimeras de Transplante , Condicionamento Pré-Transplante/métodosRESUMO
To improve health outcomes in people living with HIV, adoption of evidence-based interventions (EBIs) using effective and transferable implementation strategies to optimise the delivery of healthcare is needed. ViiV Healthcare's Positive Pathways initiative was established to support the UNAIDS 90-90-90 goals. A compendium of EBIs was developed to address gaps within the HIV care continuum, yet it was unknown whether efforts existed to adapt and implement these EBIs across diverse clinical contexts. Therefore, this review sought to report on the use of implementation science in adapting HIV continuum of care EBIs. A systematic literature review was undertaken to summarise the evaluation of implementation and effectiveness outcomes, and report on the use of implementation science in HIV care. Ten databases were reviewed to identify studies (time-period: 2013-2018; geographic scope: United States, United Kingdom, France, Germany, Italy, Spain, Canada, Australia and Europe; English only publications). Studies were included if they reported on people living with HIV or those at risk of acquiring HIV and used interventions consistent with the EBIs. A broad range of study designs and methods were searched, including hybrid designs. Overall, 118 publications covering 225 interventions consistent with the EBIs were identified. These interventions were evaluated on implementation (N = 183), effectiveness (N = 81), or both outcomes (N = 39). High variability in the methodological approaches was observed. Implementation outcomes were frequently evaluated but use of theoretical frameworks was limited (N = 13). Evaluations undertaken to assess effectiveness were inconsistent, resulting in a range of measures. This review revealed extensive reporting on implementation science as defined using evaluation outcomes. However, high variability was observed in how implementation outcomes and effectiveness were defined, quantified, and reported. A more specific and consistent approach to conducting and reporting on implementation science in HIV could facilitate achievement of UNAIDS 90-90-90 targets.
Assuntos
Medicina Baseada em Evidências/métodos , Infecções por HIV/tratamento farmacológico , Continuidade da Assistência ao Paciente , Atenção à Saúde , Infecções por HIV/diagnóstico , Infecções por HIV/virologia , Humanos , Avaliação de Resultados em Cuidados de Saúde , Resposta Viral Sustentada , Nações UnidasRESUMO
After the marathon-like challenge presented by the 16th International AIDS Conference held in Toronto a month prior--a challenge that tested the stamina of even the youngest and fittest of conference-goers--the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 27-30, 2006, in San Francisco, was a welcome relief in its staid and singular focus on the presentation of data offering insights into the challenges a variety of patients and their physicians are facing in the second decade of highly active antiretroviral therapy (HAART), as well as reviews of how to make optimal use of antiretroviral regimens constructed from within the existing HAART armamentarium. The big news at this year's ICAAC, however, was on the antiretroviral pipeline, with previews of how a new generation of drugs may help make the difference between life and death for countless millions of men, women, and children living with HIV/AIDS.
Assuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Infecções por HIV/tratamento farmacológico , Fármacos Anti-HIV/uso terapêutico , Anticorpos Monoclonais/imunologia , Colesterol/sangue , Progressão da Doença , Farmacorresistência Viral , Infecções por HIV/complicações , Hepatite C/complicações , Humanos , Ontário , Receptores CCR5/imunologiaAssuntos
Infecções por HIV/prevenção & controle , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Nevirapina/administração & dosagem , Complicações Infecciosas na Gravidez/prevenção & controle , Inibidores da Transcriptase Reversa/administração & dosagem , Feminino , Infecções por HIV/transmissão , Humanos , GravidezAssuntos
Piridazinas/uso terapêutico , Inibidores da Transcriptase Reversa/uso terapêutico , Ensaios Clínicos Fase II como Assunto , Farmacorresistência Viral , HIV/genética , HIV/isolamento & purificação , Humanos , Mutação , Nitrilas , Piridazinas/administração & dosagem , Pirimidinas , Ensaios Clínicos Controlados Aleatórios como Assunto , Inibidores da Transcriptase Reversa/administração & dosagem , Carga ViralAssuntos
Farmacorresistência Viral/genética , Infecções por HIV/tratamento farmacológico , Inibidores da Protease de HIV/uso terapêutico , Inibidores da Transcriptase Reversa/uso terapêutico , HIV/efeitos dos fármacos , Infecções por HIV/virologia , Inibidores da Protease de HIV/farmacologia , Humanos , Mutação , Inibidores da Transcriptase Reversa/farmacologiaRESUMO
A balance between survival and apoptotic signals regulates B cell development. These signals are tightly regulated by a host of molecules, including IL-7. Abnormal signaling events may lead to neoplastic transformation of progenitor B cells. Signal transduction inhibitors potentially may modulate these abnormal signals. Inhibitors of the mammalian target of rapamycin (mTOR) such as rapamycin have been used as immunosuppressive agents. We hypothesized that rapamycin might demonstrate activity against B-precursor acute lymphoblastic leukemia. We have found that rapamycin inhibited growth of B-precursor acute lymphoblastic leukemia lines in vitro, with evidence of apoptotic cell death. This growth inhibition was reversible by IL-7. One candidate as a signaling intermediate cross-regulated by rapamycin and IL-7 was p70 S6 kinase. Rapamycin also demonstrated in vivo activity in E mu-ret transgenic mice, which develop pre-B leukemia/lymphoma: E mu-ret transgenic mice with advanced disease treated daily with rapamycin as a single agent showed a >2-fold increase in length of survival as compared with symptomatic littermates who received vehicle alone. These results suggest that mammalian target of rapamycin inhibitors may be effective agents against leukemia and that one of the growth signals inhibited by this class of drugs in precursor B leukemic cells may be IL-7-mediated.